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Yeast infection in pregnancy? 
Think twice about fluconazole 
This study’s findings regarding the risk of miscarriage 
may mean it’s time to forego fluconazole in favor  
of topical azoles as first-line treatment. 
PRACTICE CHANGER
Avoid prescribing oral fluconazole in early 
pregnancy because it is associated with a 
higher rate of spontaneous abortion than is 
topical azole therapy.1 
STRENGTH OF RECOMMENDATION
B: Based on a large cohort study performed 
in Denmark.
Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association be-
tween use of oral fluconazole during pregnancy and risk of spontane-
ous abortion and stillbirth. JAMA. 2016;315:58-67.
ILLUSTRATIVE CASE
A 25-year-old woman who is 16 weeks preg-
nant with her first child is experiencing in-
creased vaginal discharge associated with 
vaginal itching. A microscopic examination of 
the discharge confirms your suspicions of vagi-
nal candidiasis. Is oral fluconazole or a topical 
azole your treatment of choice?
Because of the increased production of sex hormones, vaginal candidiasis is common during pregnancy, affecting 
up to 10% of pregnant women in the United 
States.1,2 Treatment options include oral flu-
conazole and a variety of topical azoles. Al-
though topical azoles are recommended as 
first-line therapy,3 the ease of oral therapy 
makes it an attractive treatment option.4 The 
safety of oral fluconazole during pregnancy, 
however, has recently come under scrutiny. 
Case reports have linked high-dose flu-
conazole use during pregnancy with con-
genital malformations.5,6 These case reports 
led to epidemiological studies evaluating flu-
conazole’s safety, but, in these studies, no as-
sociation with congenital malformations was 
found.7,8 
A large cohort study involving 1079 flu-
conazole-exposed pregnancies and 170,453 
unexposed pregnancies found no increased 
risk of congenital malformations or stillbirth; 
rates of spontaneous abortion and miscar-
riage were not evaluated.9 A prospective co-
hort study of 226 pregnant women found no 
association between fluconazole use during 
the first trimester and miscarriages.10 How-
ever, the validity of both studies’ findings was 
limited by small numbers of participants. The 
current study is the largest to date to evalu-
ate whether use of fluconazole compared to 
that of topical azoles in early pregnancy is as-
sociated with increased rates of spontaneous 
abortion and stillbirth.
STUDY SUMMARY
Fluconazole significantly increases  
risk of miscarriage, but not stillbirth
This nationwide cohort study, conducted us-
ing the Medical Birth Register in Denmark, 
evaluated more than 1.4 million pregnancies 
occurring from 1997 to 2013 for exposure to 
oral fluconazole between 7 and 22 weeks’ ges-
tation. Each oral fluconazole-exposed preg-
nancy was matched with up to 4 unexposed 
pregnancies (based on propensity score, ma-
ternal age, calendar year, and gestational age) 
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and to pregnancies exposed to intravaginal 
formulations of topical azoles. Exposure to 
fluconazole was documented based on filled 
prescriptions from the National Prescription 
Register. Primary outcomes were rates of 
spontaneous abortion (loss before 22 weeks) 
and stillbirth (loss after 23 weeks). 
❚ Rates of spontaneous abortion. 
From the total cohort of more than 1.4 mil-
lion pregnancies, 3315 were exposed to oral 
fluconazole between 7 and 22 weeks’ gesta-
tion. Spontaneous abortions occurred in 
147 of the 3315 fluconazole-exposed pregnan-
cies and in 563 of 13,246 unexposed, matched 
pregnancies (hazard ratio [HR]=1.48; 95% 
confidence interval [CI], 1.23-1.77). 
❚ Rates of stillbirth. Of 5382 pregnan-
cies exposed to fluconazole from week 7 to 
birth, 21 resulted in stillbirth; 77 stillbirths 
occurred in the 21,506 unexposed matched 
pregnancies (HR=1.32; 95% CI, 0.82-2.14). In 
a sensitivity analysis, however, higher doses 
of fluconazole (350 mg) were 4 times more 
likely to be associated with stillbirth (HR=4.10; 
95% CI, 1.89-8.90) than lower doses (150 mg) 
(HR= 0.99; 95% CI, 0.56-1.74). 
❚ Oral fluconazole vs topical azole. 
Use of oral fluconazole in pregnancy was 
associated with an increased risk of sponta-
neous abortion when compared to topical 
azole use: 130 of 2823 pregnancies vs 118 of 
2823 pregnancies, respectively (HR=1.62; 
95% CI, 1.26-2.07), but not an increased 
risk of stillbirths: 20 of 4301 pregnancies vs 
22 of 4301 pregnancies, respectively 
(HR=1.18; 95% CI, 0.64-2.16).
WHAT’S NEW
A sizeable study  
with a treatment comparison 
The authors found that exposure in early 
pregnancy to oral fluconazole, as compared 
to topical azoles, increases the risk of spon-
taneous abortion. By comparing treatments 
in a sensitivity analysis, the confounder of 
Candida infections causing spontaneous 
abortion was removed. In addition, when 
considering the ease of dosing of fluconazole 
as compared with topical imidazoles, this 
study challenges the balance of ease of use 
with safety. 
CAVEATS
A skewed population  
and limited generalizability?
This large cohort study using the National 
Patient Register in Denmark may not be 
generalizable to a larger, non-Scandinavian 
population. Since a hospital registry was 
used, those not seeking care through the hos-
pital were likely missed. If patients seeking 
care through the hospital had a higher risk 
of abortion, this may have biased the results. 
However, this would not have affected the re-
sults for the comparison between the 2 active 
treatments. 
In addition, the study focused on women 
exposed from 7 to 22 weeks’ gestation; the 
findings may not be generalizable to flucon-
azole exposure prior to 7 weeks. Likewise, the 
registry is unlikely to capture very early spon-
taneous abortions that are not recognized 
clinically. In all, given the large sample size 
and the care taken to match each exposed 
pregnancy with up to 4 unexposed pregnan-
cies, these limitations are likely to have had 
little influence on the overall findings of 
the study. 
CHALLENGES TO IMPLEMENTATION
Balancing ease of use with safety
Given the ease of using oral fluconazole vs 
daily topical azole therapy, many physicians 
and patients may still opt for oral treatment.    JFP
ACKNOWLEDGEMENT
The PURLs Surveillance System was supported in part by 
Grant Number UL1RR024999 from the National Center For 
Research Resources, a Clinical Translational Science Award to 
the University of Chicago. The content is solely the responsi-
bility of the authors and does not necessarily represent the 
official views of the National Center For Research Resources 
or the National Institutes of Health.
Copyright © 2016. The Family Physicians Inquiries Network. 
All rights reserved. 
References
 1.   Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association 
between use of oral fluconazole during pregnancy and risk of 
spontaneous abortion and stillbirth. JAMA. 2016;315:58-67.
 2.   Cotch MF, Hillier SL, Gibbs RS, et al. Epidemiology and outcomes 
associated with moderate to heavy Candida colonization during 
pregnancy. Vaginal Infections and Prematurity Study Group. Am 
J Obstet Gynecol. 1998;178:374-380.
 3.   Workowski KA, Bolan GA, Centers for Disease Control and Pre-
vention. Sexually transmitted diseases treatment guidelines, 
2015. MMWR Recomm Rep. 2015;64:1-137.
 4.   Tooley PJ. Patient and doctor preferences in the treatment of vagi-
Given the ease 
of using oral  
fluconazole vs 
daily topical 
azole therapy, 
many physicians 
and patients 
may still opt  
for oral  
treatment. 
626 THE JOURNAL OF FAMILY PRACTICE  |   SEPTEMBER 2016  |   VOL 65, NO 9
PURLs®
nal candidosis. Practitioner. 1985;229: 655-660. 
 5.   Aleck KA, Bartley DL. Multiple malformation syndrome following 
fluconazole use in pregnancy: report of an additional patient. Am 
J Med Genet. 1997;72:253-256. 
 6.   Lee BE, Feinberg M, Abraham JJ, et al. Congenital malformations 
in an infant born to a woman treated with fluconazole. Pediatr 
Infect Dis J. 1992;11:1062-1064.
 7.   Jick SS. Pregnancy outcomes after maternal exposure to flucon-
azole. Pharmacotherapy. 1999;19:221-222.
 8.   Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral flucon-
azole during pregnancy and the risk of birth defects. N Engl J Med. 
2013;369:830-839.
 9.   Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of flucon-
azole and risk of congenital malformations: a Danish population-
based cohort study. J Antimicrob Chemother. 2008;62:172-176.
 10.   Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assess-
ment of pregnancy outcomes after first-trimester exposure to flu-
conazole. Am J Obstet Gynecol. 1996;175:1645-1650.
